Last reviewed · How we verify
Immediate-Release Aspirin Tablets
Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes to reduce platelet aggregation and inflammation.
Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes to reduce platelet aggregation and inflammation. Used for Cardiovascular event prevention (secondary prevention post-myocardial infarction or stroke), Pain and fever relief, Inflammatory conditions.
At a glance
| Generic name | Immediate-Release Aspirin Tablets |
|---|---|
| Sponsor | PLx Pharma |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent |
| Target | Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Aspirin acetylates serine residues on COX-1 and COX-2, preventing the synthesis of prostaglandins and thromboxane A2. This reduces platelet activation and aggregation, thereby decreasing thrombotic events, and also provides anti-inflammatory and analgesic effects through reduced prostaglandin production in tissues.
Approved indications
- Cardiovascular event prevention (secondary prevention post-myocardial infarction or stroke)
- Pain and fever relief
- Inflammatory conditions
Common side effects
- Gastrointestinal bleeding or ulceration
- Dyspepsia
- Nausea
- Hemorrhage (minor)
- Allergic reactions (rare)
Key clinical trials
- Pathways of Eicosanoid Metabolism (EARLY_PHASE1)
- Randomized, Crossover Bioequivalence Study of PL-ASA Versus Immediate Release Aspirin in Healthy Volunteers. (PHASE1)
- Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients (PHASE3)
- A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers (PHASE3)
- Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers (PHASE3)
- Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers (PHASE3)
- Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) and in a Combination of Persantin Immediate Release Tablets and ASA Tablets in Healthy Subjects (PHASE1)
- A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |